These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27500861)

  • 1. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders.
    Williams WP; McLin DE; Dressman MA; Neubauer DN
    Pharmacotherapy; 2016 Sep; 36(9):1028-41. PubMed ID: 27500861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
    Laudon M; Frydman-Marom A
    Int J Mol Sci; 2014 Sep; 15(9):15924-50. PubMed ID: 25207602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Circadian Rhythm Sleep-Wake Disorders.
    Sun SY; Chen GH
    Curr Neuropharmacol; 2022; 20(6):1022-1034. PubMed ID: 34493186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R
    Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN
    Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tasimelteon approved for circadian disorder in blind adults.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(5):350. PubMed ID: 24534583
    [No Abstract]   [Full Text] [Related]  

  • 9. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders.
    Geoffroy PA; Etain B; Franchi JA; Bellivier F; Ritter P
    Curr Pharm Des; 2015; 21(23):3352-8. PubMed ID: 26088111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM
    CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
    Emens JS; Eastman CI
    Drugs; 2017 Apr; 77(6):637-650. PubMed ID: 28229310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tasimelteon: first global approval.
    Dhillon S; Clarke M
    Drugs; 2014 Mar; 74(4):505-11. PubMed ID: 24610704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin agonists and insomnia.
    Ferguson SA; Rajaratnam SM; Dawson D
    Expert Rev Neurother; 2010 Feb; 10(2):305-18. PubMed ID: 20136385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the pharmacological management of non-24-h sleep-wake disorder.
    Nishimon S; Nishino N; Nishino S
    Expert Opin Pharmacother; 2021 Jun; 22(8):1039-1049. PubMed ID: 33618599
    [No Abstract]   [Full Text] [Related]  

  • 18. Circadian Rhythm Sleep-Wake Disorders: a Contemporary Review of Neurobiology, Treatment, and Dysregulation in Neurodegenerative Disease.
    Steele TA; St Louis EK; Videnovic A; Auger RR
    Neurotherapeutics; 2021 Jan; 18(1):53-74. PubMed ID: 33844152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Workshop report. Circadian rhythm sleep-wake disorders: gaps and opportunities.
    Duffy JF; Abbott SM; Burgess HJ; Crowley SJ; Emens JS; Epstein LJ; Gamble KL; Hasler BP; Kristo DA; Malkani RG; Rahman SA; Thomas SJ; Wyatt JK; Zee PC; Klerman EB
    Sleep; 2021 May; 44(5):. PubMed ID: 33582815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circadian rhythm sleep-wake disorder (circadian rhythm sleep disorder)].
    Tagaya H; Murayama N; Fukase Y
    Nihon Rinsho; 2015 Jun; 73(6):942-8. PubMed ID: 26065124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.